DDInter458 DDInter817
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status.
Cyclosporine {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gilteritinib
Cyclosporine {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Pentamidine
Pentamidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Cyclosporine {u} (Compound) upregulates {v} (Gene) SLC1A4
SLC1A4 {u} (Gene) is upregulated by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gilteritinib
Cyclosporine {u} (Compound) downregulates {v} (Gene) PCNA
PCNA {u} (Gene) is downregulated by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gilteritinib
Cyclosporine {u} (Compound) upregulates {v} (Gene) SLC1A4
SLC1A4 {u} (Gene) is upregulated by {v} (Compound) Pentamidine
Pentamidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Cyclosporine {u} (Compound) causes {v} (Side Effect) Purpura
Purpura {u} (Side Effect) is caused by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Gilteritinib
Cyclosporine {u} (Compound) downregulates {v} (Gene) PCNA
PCNA {u} (Gene) is downregulated by {v} (Compound) Atorvastatin
Atorvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Cyclosporine {u} (Compound) causes {v} (Side Effect) Purpura
Purpura {u} (Side Effect) is caused by {v} (Compound) Oxcarbazepine
Oxcarbazepine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gilteritinib
Cyclosporine {u} (Compound) upregulates {v} (Gene) SLC1A4
SLC1A4 {u} (Gene) is upregulated by {v} (Compound) Saquinavir
Saquinavir {u} may lead to a major life threatening interaction when taken with {v} Gilteritinib
Cyclosporine {u} (Compound) causes {v} (Side Effect) Thrombocytopenic purpura
Thrombocytopenic purpura {u} (Side Effect) is caused by {v} (Compound) Pimozide
Pimozide {u} may lead to a major life threatening interaction when taken with {v} Gilteritinib
Cyclosporine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Cyclosporine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Pentamidine (Compound) and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Cyclosporine (Compound) upregulates SLC1A4 (Gene) and SLC1A4 (Gene) is upregulated by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Cyclosporine (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Cyclosporine (Compound) upregulates SLC1A4 (Gene) and SLC1A4 (Gene) is upregulated by Pentamidine (Compound) and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Cyclosporine (Compound) causes Purpura (Side Effect) and Purpura (Side Effect) is caused by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Cyclosporine (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Atorvastatin (Compound) and Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Cyclosporine (Compound) causes Purpura (Side Effect) and Purpura (Side Effect) is caused by Oxcarbazepine (Compound) and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Cyclosporine (Compound) upregulates SLC1A4 (Gene) and SLC1A4 (Gene) is upregulated by Saquinavir (Compound) and Saquinavir may lead to a major life threatening interaction when taken with Gilteritinib
Cyclosporine (Compound) causes Thrombocytopenic purpura (Side Effect) and Thrombocytopenic purpura (Side Effect) is caused by Pimozide (Compound) and Pimozide may lead to a major life threatening interaction when taken with Gilteritinib